0001787306-24-000085.txt : 20240531 0001787306-24-000085.hdr.sgml : 20240531 20240531165040 ACCESSION NUMBER: 0001787306-24-000085 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240529 FILED AS OF DATE: 20240531 DATE AS OF CHANGE: 20240531 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burnett Patrick CENTRAL INDEX KEY: 0001741987 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39186 FILM NUMBER: 241010536 MAIL ADDRESS: STREET 1: C/O VERRICA PHARMACEUTICALS INC. STREET 2: 10 NORTH HIGH STREET, SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arcutis Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001787306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812974255 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3027 TOWNSGATE ROAD STREET 2: SUITE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 BUSINESS PHONE: 805-418-5006 MAIL ADDRESS: STREET 1: 3027 TOWNSGATE ROAD STREET 2: SUITE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91361 FORMER COMPANY: FORMER CONFORMED NAME: Arcutis, Inc. DATE OF NAME CHANGE: 20190905 4 1 wk-form4_1717188632.xml FORM 4 X0508 4 2024-05-29 0 0001787306 Arcutis Biotherapeutics, Inc. ARQT 0001741987 Burnett Patrick C/O ARCUTIS BIOTHERAPEUTICS, INC. 3027 TOWNSGATE ROAD SUITE 300 WESTLAKE VILLAGE CA 91361 0 1 0 0 See Remarks 0 Common Stock 2024-05-29 4 S 0 49952 8.7161 D 209793 D Common Stock 2024-05-30 4 M 0 23000 0 A 232793 D Common Stock 2024-05-30 4 S 0 23000 8.753 D 209793 D Stock Option (right to buy) 3.64 2024-05-30 4 M 0 23000 0 D 2034-01-12 Common Stock 23000 253000 D The transaction was executed in multiple trades in prices ranging from $8.50 to $8.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $8.70 to $8.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer. Reporting Person's title: SVP Chief Medical Officer /s/ David Topper, as Attorney-in-Fact for Patrick Burnett 2024-05-31